Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Indirect Treatment Comparison of Lurbinectedin vs. Other Second-Line Treatments for Small-Cell Lung Cancer

(2022) B. Rengarajan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

(2021) María Eugenia Olmedo et al.   INVESTIGATIONAL NEW DRUGS

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

(2021) A.-M.C. Dingemans et al.   ANNALS OF ONCOLOGY

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

(2020) José Trigo et al.   LANCET ONCOLOGY

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

(2020) Nathalie Baize et al.   LANCET ONCOLOGY

Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review

(2020) Pietro Lapidari et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

(2019) Wei Xie et al.   OncoImmunology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

(2018) Anna F Farago et al.   Future Oncology

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

(2016) Koichi Goto et al.   LANCET ONCOLOGY

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

(2016) G. Santamaria Nunez et al.   MOLECULAR CANCER THERAPEUTICS

Abstract 2542: Lurbinectedin (PM01183) synergizes in vivo the antitumor activity of doxorubicin in SCLC tumor xenografts

(2015) Maria Jose Guillen et al.   CANCER RESEARCH

Treating Transcriptional Addiction in Small Cell Lung Cancer

(2014) Arnaud Augert et al.   CANCER CELL

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY